Human Apolipoprotein B/ApoB Antibody

Detection of Apolipoprotein B/ApoB by Western Blot

Particle number increases proportionally with needle-to-processing time. (a) A set of four peripheral blood samples was each collected in n=4 biological replicates Streck Cell-Free DNA BCT. EV enrichment was performed by differential ultracentrifugation (dUC), followed by SEC. EV-enriched fractions were analyzed by NTA, BCA and WB. (b) Particle numbers obtained from the different needle-to-processing times, measured by NTA. Data normalized to the control condition of immediately processed blood. Mean of normalized value is displayed for each needle-to-processing time and statistical significance is assessed using one sample t test (Bonferroni-Holm-adjusted p-values) with *p=0.0175 (24 h), **p=0.0033 (72 h) and **p=0.0033 (1 week). (c) Median size of particles recovered in EV-enriched fractions from the different needle-to-processing times. Mean value is displayed for each needle-to-processing time and statistical significance is assessed using paired t test (Bonferroni-Holm-adjusted p-values) with **p=0.0014 (24 h vs. immediate processing), ***p=0.0006 (72 h vs. immediate processing) and ***p=0.0006 (1 week vs. immediate processing). In (b) and (c) symbols signify independent biological replicates. (d) Representative immunoblotting image to characterize particles obtained according to EV markers, cell-specific markers and apolipoprotein markers. Original blots are presented in Supplementary Fig. S10 online. (e)-(g) Quantification of band intensities in (d). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/40624148), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Apolipoprotein B/ApoB by Western Blot

Density gradient ultracentrifugation combined with size exclusion chromatography and ultrafiltration recovers high particle numbers and reduces co-isolates. (a) A set of three peripheral blood samples was each collected in n=3 biological replicates in Streck Cell-Free DNA BCT. EVs were isolated using either differential ultracentrifugation (dUC) or density gradient ultracentrifugation (DG), followed by SEC. Following SEC, DG-purified EVs were concentrated either by ultracentrifugation (DG+UC) or by ultrafiltration (DG+UF). EV-enriched fractions were analyzed by nanoparticle tracking analysis (NTA) and western blot (WB). (b) Total particle recovery and (c) median particle size measured by NTA in EV-enriched fractions using different combinations of purification methods. In (b) and (c) mean values are displayed for each processing condition, and in (b) statistical significance is assessed using paired t test (DG+UC vs. DG+UF) with *p=0.0311. In (b) and (c) symbols signify independent biological replicates. (d) Representative immunoblotting of EV-enriched fractions obtained with the different strategies. Original blots are presented in Supplementary Fig. S11 online. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/40624148), licensed under a CC-BY license. Not internally tested by R&D Systems.